生命科学资讯

Astellas tops expectations as Vyloy sales surge outshines trial setback

Racing BMS and J&J, Bayer links asundexian to 26% stroke reduction to unblock path to FDA

A hack-proof internet? Quantum encryption could be the key

Veradermics CEO has a great hair day with 122% pop in IPO

Novo, Lilly sputter as Hims launches knockoff GLP-1 pill

#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial

Bayer details anticipated stroke prevention data for new blood-thinner

Generate, an AI-driven Flagship startup, pitches an IPO

Meningeal blood vessel blockage enhances anti-glioblastoma immunity

Molecular architecture of human dermal sleeping nociceptors

Divergent tumor immunity determined by bacteria-cancer cell engagement

Flagship-founded antibody biotech Generate is latest to mull IPO

A cut above: Veradermics locks in $256M IPO and shares spike

Angitia raises $130M to challenge Amgen with bone-building bispecifics

GE HealthCare posts higher full-year revenues amid turbulent tariff backdrop

Bristol Myers draws pipeline excitement as several data readouts near

GLP-1s and the Super Bowl

Inside the quest to make a safer football helmet

Thermo Fisher, Charles River workforce cuts; WuXi signs contract with Vertex

Illumina earnings loom as investors seek clarity on 2026 outlook By Investing.com - Investing.com